@FierceMedDev: ICYMI: Here's yesterday's issue of FierceDrugDelivery. | Follow @FierceMedDev
@StacyALawrence: You're so fierce: A call for nominations of the top women in med tech. Editor's corner | Follow @StacyALawrence
@VarunSaxena2: Big VC scoop from my colleague @StacyALawrence: Sofinnova spinoff HealthQuest targets $110M, makes first investments. News | Follow @VarunSaxena2
@EmilyWFierce: ICYMI yesterday: Medicated electrospun fabric offers alternative delivery method for HIV-preventing drugs. FierceDrugDelivery story | Follow @EmilyWFierce
> Validic, a mobile healthcare device connection platform, closed a Series A investment round with $5 million raised. More
> Researchers at the University of California, San Diego, created a temporary tattoo that can turn the wearer's sweat into a modest electrical current. More
> Harvard University's endowment invested in 400,000 shares of Covidien ($COV) stock before news of the Medtronic ($MDT) merger was made public. More
Biotech News
@FierceBiotech: Merck wins FDA nod for a weaker form of its embattled sleep drug. Article | Follow @FierceBiotech
@DamianFierce: ICYMI yesterday: $MRK's suvorexant will sell as Belsomra, but dosing issue will likely limit its market value. Article | Follow @DamianFierce
@EmilyMFierce: Sanofi's high-dose Fluzone beats standard-dose version in protecting seniors. Story | Follow @EmilyMFierce
> InterMune buyout rumors resurface, with Roche, Sanofi on the short list. More
> Allergan bets up to $588M on Taris' bladder candidate. News
> Prefer a Swiss tax rate? Basilea chief says he's ready to parley. Story
> AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown. Article
Pharma News
@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Want more? Subscribe here. | Follow @FiercePharma
@EricPFierce: ICYMI yesterday: Merck KGaA has to rely on AZ as its pharma sales contract in Q2. Article | Follow @EricPFierce
@CarlyHFierce: Sovaldi payer pushback hurting access for opioid treatment patients. Story | Follow @CarlyHFierce
> InterMune takeover talk is tantalizing, but are investors too optimistic? Report
> Merck's sleep drug suvorexant overcomes hurdles to win FDA approval. Article
> The irrational rationale for cancer drug prices, with Novartis' Zykadia as exhibit A. Story
Vaccines News
> Sanofi's high-dose Fluzone beats standard-dose version in protecting seniors. More
> Researchers retract narcolepsy study linked to Glaxo's Pandemrix. Report
> Health Canada signs off on GSK's plans to improve its flu vaccine plant. More
> Pfizer's Prevnar gets $2B boost with CDC nod in older adults. Article
> Dendreon's debt plans could leave stockholders in the lurch. Story
Pharma Manufacturing News
> Shire takes over production of Buccolam after contractor fails. Article
> Amgen recalls Aranesp syringes contaminated with polyester. Report
> Indian regulator lays down new standards for its inspectors. More
> Baxter recalls another lot of saline solution as shortage persists. Story
> Canada says GSK flu vaccine plant is on track; the FDA remains mum. Item
> Wockhardt's run-ins with the FDA cost it most of its profits for a quarter. Article